肾素抑制剂阿利吉仑在非糖尿病肾小球疾病治疗中的应用前景  

Application prospect of renin inhibitor Aliskiren in the treatment of nondiabetic glomerulonephritis

作　　者：伍巧源[1] 廖蕴华[1] WU Qiao-yuan LIAO Yun-hua(Department of Nephrology,the First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学第一附属医院肾内科,广西南宁530021

出　　处：《中国当代医药》2017年第5期18-21,共4页China Modern Medicine

基　　金：广西状族自治区自然科学基金项目(2013GXNSF AA019169)

摘　　要：非糖尿病性肾小球疾病是导致终末期肾病(end stage renal disease,ESRD)的常见原因。慢性肾脏病进展到一定阶段后均通过肾小管间质纤维化共同途径发展到ESRD,该过程中肾素-血管紧张素-醛固酮系统(RAAS)扮演重要的作用。阻断RAAS系统能延缓慢性肾脏病的进展;ACEI或ARB在肾脏疾病治疗上确实起到重要作用,但仍不令人满意,部分患者蛋白尿仍持续存在。阿利吉仑是第一个非肽类直接肾素抑制剂,不仅可直接作用于RAAS,还可抑制PRR/MAPK/ERK信号通路而起到抗纤维化作用。本文致力于阐述其应用于肾小球疾病的治疗前景。Non-diabetic glomerulonephritis is a common cause of end stage renal disease（ESRD）.The development of chronic kidney diseases（CKD） to a certain stage is through the common pathway of renal tubule interstitial fibrosis to ESRD,and renin-angiotensin-aldosterone system（RAAS） plays an important role during the process.Blocking RAAS system can delay the progress of CKD.Angiotensin-converting enzyme inhibitor（ACEI） or angiotensin receptor blocker（ARB） exerts a great role,but which still is not satisfying due to persisted proteinuria in some patients.Aliskiren is the first non-peptide direct renin inhibitor,which not only directly influences on RAAS,also blocks the PRR/MAPK/ERK signal pathway with anti-fibrosis.The paper focused on the prospect of applying Aliskiren to glomerulopathy.

关 键 词：非糖尿病性肾小球疾病 肾素-血管紧张素-醛固酮系统 阿利吉仑 

分 类 号：R692.6[医药卫生—泌尿科学]